FitLife Brands Details Executive Equity Compensation in DEF 14A
Ticker: FTLF · Form: DEF 14A · Filed: Jun 24, 2025 · CIK: 1374328
Sentiment: neutral
Topics: Executive Compensation, Equity Awards, DEF 14A, Shareholder Dilution, Corporate Governance, Medicinal Chemicals, Proxy Statement
Related Tickers: FTLF
TL;DR
**FTLF's executive compensation is heavily tied to equity, signaling a focus on long-term performance but watch for potential dilution.**
AI Summary
FITLIFE BRANDS, INC. (FTLF) filed a DEF 14A on June 24, 2025, for the period ending December 31, 2024, indicating a focus on executive compensation and governance. The filing details equity award adjustments for both named executive officers (PEO) and non-PEO members across 2022, 2023, and 2024. Specifically, the company reported adjustments for equity awards, including option and stock awards, for PEOs in 2024. The fair value of equity awards granted and vested in 2024 for PEOs was detailed, alongside changes in fair value of prior year equity awards vested in 2024. The document also outlines the year-end fair value of equity awards granted in 2024 that remain outstanding and unvested for PEOs. While specific revenue and net income figures are not directly provided in this DEF 14A, the detailed compensation structure suggests ongoing operational activities and a strategic outlook that includes incentivizing executive performance through equity. Risks related to compensation structure and shareholder dilution are implicitly present.
Why It Matters
This DEF 14A filing provides crucial transparency into FITLIFE BRANDS, INC.'s executive compensation practices, particularly regarding equity awards for 2022-2024. For investors, understanding these compensation structures is vital for assessing potential shareholder dilution and alignment of executive incentives with long-term company performance. Employees, especially those with equity, can gauge the company's approach to stock-based compensation. In a competitive market, robust and transparent compensation plans can attract and retain top talent, impacting the company's ability to innovate and grow in the medicinal chemicals and botanical products sector.
Risk Assessment
Risk Level: medium — The filing details significant equity award adjustments and fair value changes for executive compensation across 2022-2024, including option and stock awards. While designed to align interests, a heavy reliance on equity compensation can lead to shareholder dilution if not managed effectively, posing a medium risk to existing shareholders.
Analyst Insight
Investors should scrutinize the full proxy statement to understand the total compensation packages and the performance metrics tied to these equity awards. Evaluate the potential for dilution from these awards and how they align with FITLIFE BRANDS, INC.'s overall financial health and growth strategy.
Key Numbers
- 2024 — Fiscal Year (period for which executive compensation data is detailed)
- 2022 — Fiscal Year (earliest period for which executive compensation data is detailed)
- 2023 — Fiscal Year (mid-period for which executive compensation data is detailed)
- 19 — Public Document Count (number of documents in the filing)
- 001-41803 — SEC File Number (identifies the company's registration statement)
Key Players & Entities
- FITLIFE BRANDS, INC. (company) — filer of DEF 14A
- SEC (regulator) — recipient of filing
- 0001374328 (company) — Central Index Key (CIK) for FITLIFE BRANDS, INC.
- BOND LABORATORIES, INC. (company) — former name of FITLIFE BRANDS, INC.
- 03 Life Sciences (company) — organization name associated with the filer
- Nevada (state) — state of incorporation for FITLIFE BRANDS, INC.
- Omaha (city) — business address city for FITLIFE BRANDS, INC.
- NE (state) — business address state for FITLIFE BRANDS, INC.
- 2025-06-24 (date) — filing date of DEF 14A
- 2025-08-12 (date) — conformed period of report
FAQ
What is the purpose of FITLIFE BRANDS, INC.'s DEF 14A filing?
The DEF 14A filing by FITLIFE BRANDS, INC. (FTLF) on June 24, 2025, primarily serves to provide shareholders with information regarding matters to be voted upon at the upcoming annual meeting, including detailed disclosures on executive compensation, specifically equity awards for 2022, 2023, and 2024.
What specific compensation details are included in FTLF's DEF 14A?
The DEF 14A includes specific details on the fair value of equity awards granted and vested in 2024 for named executive officers (PEO), changes in the fair value of prior year equity awards vested in 2024, and the year-end fair value of outstanding and unvested equity awards granted in 2024 for PEOs.
How does FITLIFE BRANDS, INC. compensate its executives according to this filing?
According to the DEF 14A, FITLIFE BRANDS, INC. compensates its executives, particularly named executive officers (PEO), through equity awards, including both option awards and stock awards, with detailed adjustments and fair value calculations provided for the fiscal years 2022, 2023, and 2024.
What are the potential risks associated with FTLF's executive compensation structure?
A potential risk associated with FITLIFE BRANDS, INC.'s executive compensation structure, heavily reliant on equity awards, is shareholder dilution. While designed to align executive interests with long-term company performance, an excessive issuance of stock or options can dilute the value of existing shares.
When was FITLIFE BRANDS, INC.'s DEF 14A filed?
FITLIFE BRANDS, INC.'s DEF 14A was filed on June 24, 2025, with the conformed period of report being August 12, 2025.
What industry does FITLIFE BRANDS, INC. operate in?
FITLIFE BRANDS, INC. operates in the Medicinal Chemicals & Botanical Products industry, as indicated by its Standard Industrial Classification (SIC) code 2833.
Where is FITLIFE BRANDS, INC. headquartered?
FITLIFE BRANDS, INC. is headquartered at 5214 S. 136th Street, Omaha, Nebraska 68137, with a business phone number of 402-884-1894.
What was FITLIFE BRANDS, INC. formerly known as?
FITLIFE BRANDS, INC. was formerly known as BOND LABORATORIES, INC., with the name change occurring on August 31, 2006.
How can investors use the information in this DEF 14A filing?
Investors can use the information in this DEF 14A filing to understand the company's executive compensation philosophy, assess the potential impact of equity awards on shareholder value, and inform their voting decisions on proposals related to executive pay and corporate governance at the upcoming annual meeting.
Does the DEF 14A provide revenue or net income figures for FITLIFE BRANDS, INC.?
No, this specific DEF 14A filing primarily focuses on executive compensation details, particularly equity awards and their fair values for 2022-2024. It does not directly provide revenue or net income figures for FITLIFE BRANDS, INC.
Industry Context
FITLIFE BRANDS, INC. operates within the medicinal chemicals and botanical products sector (SIC 2833). This industry is characterized by rigorous regulatory oversight, significant research and development investment, and a competitive landscape driven by innovation and market access. Trends include the growing demand for specialized health and wellness products, advancements in biotechnology, and evolving consumer preferences for natural and plant-based ingredients.
Regulatory Implications
As a company in the medicinal and botanical products sector, FITLIFE BRANDS, INC. is subject to stringent regulations from bodies like the FDA concerning product safety, efficacy, and manufacturing practices. The DEF 14A filing itself is a regulatory requirement under the Securities Exchange Act of 1934, mandating transparency in executive compensation and corporate governance.
What Investors Should Do
- Review executive compensation details for alignment with company performance.
- Analyze equity award trends and fair value changes.
- Evaluate governance practices outlined in the proxy statement.
Key Dates
- 2025-06-24: DEF 14A Filing — Indicates the company is providing detailed information on executive compensation and governance for the fiscal year ending December 31, 2024.
- 2025-08-12: Conformed Period of Report — Specifies the end date of the reporting period covered by the DEF 14A filing.
- 2024-12-31: Fiscal Year End — The period for which the executive compensation and equity award data in the DEF 14A filing is primarily reported.
- 2023-12-31: Fiscal Year End — Represents a prior year for which executive compensation and equity award data is provided for comparison.
- 2022-12-31: Fiscal Year End — Represents the earliest year for which executive compensation and equity award data is provided in the filing.
Glossary
- DEF 14A
- A Definitive Proxy Statement filed with the SEC, typically used to solicit proxies from shareholders for an annual or special meeting of shareholders. It contains detailed information about matters to be voted on, including executive compensation and corporate governance. (This filing provides the core data on executive compensation and equity awards for FITLIFE BRANDS, INC.)
- PEO
- Principal Executive Officer, referring to the top executive officer of a company, typically the CEO. (The filing details equity award adjustments specifically for PEOs for the fiscal years 2022, 2023, and 2024.)
- Non-PEO Neo Member
- Refers to members of the Board of Directors who are not executive officers, often referred to as 'outside directors' or 'independent directors'. (The filing also provides data on equity award adjustments for these non-executive board members.)
- Equity Awards
- Awards granted to employees or directors that are based on the value of the company's stock, such as stock options, restricted stock units (RSUs), or stock appreciation rights (SARs). (The DEF 14A extensively details adjustments and fair values of various equity awards granted to executives and non-executive members.)
- Fair Value
- The estimated price at which an asset would change hands between a willing buyer and a willing seller, neither being under any compulsion to buy or to sell and both having reasonable knowledge of relevant facts. (The filing reports the fair value of equity awards granted, vested, and outstanding, which is a key metric for understanding compensation value.)
- Option Awards
- A type of equity award that gives the holder the right, but not the obligation, to purchase a company's stock at a predetermined price (the exercise price) within a specified period. (The filing includes adjustments and reported values for option awards granted to PEOs and Non-PEO Neo Members.)
- Stock Awards
- A type of equity award where the company grants shares of its stock directly to an employee or director, often subject to vesting conditions. (The filing details adjustments and reported values for stock awards granted to PEOs and Non-PEO Neo Members.)
Year-Over-Year Comparison
This DEF 14A filing focuses on executive compensation and governance for the fiscal year ending December 31, 2024, detailing equity award adjustments for PEOs and Non-PEO Neo Members across 2022-2024. While specific financial performance metrics like revenue and net income are not directly presented in this document, the emphasis on equity awards suggests a strategy to align executive incentives with company performance. A comparison to a prior filing would require access to previous proxy statements to track changes in compensation philosophy, award values, and potential shifts in governance practices.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on June 24, 2025 regarding FITLIFE BRANDS, INC. (FTLF).